-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Opthea (NASDAQ:OPT) Shares Up 3.4%
Opthea (NASDAQ:OPT) Shares Up 3.4%
Opthea Limited (NASDAQ:OPT – Get Rating)'s stock price shot up 3.4% during trading on Tuesday . The company traded as high as $7.00 and last traded at $7.00. 691 shares traded hands during trading, a decline of 44% from the average session volume of 1,225 shares. The stock had previously closed at $6.77.
Analyst Upgrades and Downgrades
A number of research firms recently commented on OPT. SVB Leerink began coverage on shares of Opthea in a research report on Tuesday, April 26th. They set an "outperform" rating and a $25.00 price target on the stock. Truist Financial lowered their price target on shares of Opthea from $25.00 to $13.00 in a research report on Wednesday, April 13th.
Get Opthea alerts:Opthea Stock Up 3.4 %
The firm's fifty day simple moving average is $6.50 and its 200 day simple moving average is $6.28.
Hedge Funds Weigh In On Opthea
An institutional investor recently raised its position in Opthea stock. Victory Capital Management Inc. grew its stake in Opthea Limited (NASDAQ:OPT – Get Rating) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,596,207 shares of the company's stock after purchasing an additional 21,513 shares during the period. Victory Capital Management Inc. owned about 3.63% of Opthea worth $9,817,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.83% of the company's stock.Opthea Company Profile
(Get Rating)
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Articles
- Get a free copy of the StockNews.com research report on Opthea (OPT)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
- Pinterest Shares Are Soaring After Earnings, Is The Stock A Buy?
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
Opthea Limited (NASDAQ:OPT – Get Rating)'s stock price shot up 3.4% during trading on Tuesday . The company traded as high as $7.00 and last traded at $7.00. 691 shares traded hands during trading, a decline of 44% from the average session volume of 1,225 shares. The stock had previously closed at $6.77.
在週二的交易中，Opthea Limited(納斯達克代碼：OPT-GET Rating)的股價飆升3.4%。該公司股價一度漲至7.00美元，最新報7.00美元。691股股票在交易中易手，較1,225股的平均成交量下跌44%。該股此前收盤報6.77美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of research firms recently commented on OPT. SVB Leerink began coverage on shares of Opthea in a research report on Tuesday, April 26th. They set an "outperform" rating and a $25.00 price target on the stock. Truist Financial lowered their price target on shares of Opthea from $25.00 to $13.00 in a research report on Wednesday, April 13th.
一些研究公司最近對OPT發表了評論。SVB Leerink在4月26日星期二的一份研究報告中開始報道Opthea的股票。他們為該股設定了“跑贏大盤”的評級和25.00美元的目標價。在4月13日星期三的一份研究報告中，Truist Financial將Opthea的股票目標價從25.00美元下調至13.00美元。
Opthea Stock Up 3.4 %
Opthea股價上漲3.4%
The firm's fifty day simple moving average is $6.50 and its 200 day simple moving average is $6.28.
該公司的50日簡單移動均線為6.50美元，200日簡單移動均線為6.28美元。
Hedge Funds Weigh In On Opthea
對衝基金對Opthea的看法
Opthea Company Profile
Opthea公司簡介
(Get Rating)
(獲取評級)
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Opthea有限公司是一家臨牀階段的生物製藥公司，主要在澳大利亞開發和銷售治療眼病的藥物。該公司的開發活動基於知識產權組合，包括用於治療與血管和淋巴管生長以及血管滲漏相關的疾病的血管內皮細胞生長因子(VEGFC)、VEGFD和VEGFR3。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Opthea (OPT)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
- Pinterest Shares Are Soaring After Earnings, Is The Stock A Buy?
- 免費獲取StockNews.com關於Opthea的研究報告(OPT)
- 大財務健康中的3只醫療保健類股
- 亞馬遜稱自己是第三季度競爭者的首選股票
- 萬億美元市值的意義不僅僅是數字
- 市場基本面推動威廉姆斯公司的業績
- Pinterest股價在盈利後飆升，A股買入嗎？
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
接受Opthea Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Opthea和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧